联合使用思力华和舒利迭治疗稳定期慢性阻塞性肺疾病患者肺功能的综合评价  

Comprehensive assessment on tiotropium combined with seretide in the treatment of stable chronic obstructive pulmonary disease

作　　者：庞健辉[1] 林淑媚[1] 峗淑莉[1] 朱模寿[1] 

机构地区：[1]广东省中山市陈星海医院,广东中山528415

出　　处：《吉林医学》2017年第4期670-672,共3页Jilin Medical Journal

基　　金：中山市卫计局科研立项结题论文(项目编号:中山市卫计局2014J217)

摘　　要：目的:对联合使用思力华和舒利迭治疗稳定期慢性阻塞性肺疾病(COPD)患者的肺功能及其临床疗效、疗程进行综合评价。方法:将50例COPD稳定期患者随机分为2组,治疗组联合使用思力华和舒利迭进行治疗,对照组仅使用舒利迭进行治疗。监测两组患者治疗前后的肺功能指标;观察治疗疗程、并随访复发率的发生情况。结果:联合用药的治疗组FEV1占预计值百分比和FEV1/FVC较对照组患者,均有显著改善,且差异具有统计学意义(P<0.05)。联合用药治疗的患者的临床症状消失时间、X线片显示恢复正常的时间以及住院时间均显著短于对照组,且差异均具有统计学意义(P<0.05)。随着治疗疗程的减少,治疗组的治疗总费用与对照组相比相当。随访半年期间治疗组患者有一半以上痊愈,痊愈率(52%)显著高于对照组(24%),且差异具有统计学意义(P<0.05);复发率(8%)显著低于对照组(32%),差异具有统计学意义(P<0.05)。结论:联合使用思力华和舒利迭治疗疗程短,而且病情复发率较低,总费用不高,且两药联用的效果比较好,具有广阔的应用前景,是值得推广的临床治疗方案之一。Objective To assess the comprehensive effect of tiotropium combined with seretide in the treatment of stable COPD patients.Method 50 patients were divided into 2 groups,the patients in curative group were treated by tiotropium combined with seretide,the patients in control group were treated only by seretide.Their pulmonary function,period of treatment,recurrence were observed.Results FEV1（ %） and FEV1/FVC which reflected the pulmonary function were significantly improved in the curative group（ P〈0.05）.The disappearance time of clinical symptoms,the time of recovery of X-ray an the time of hospitalization were significantly shorter than those of control group（ P〈0.05）.With the reduction of the treatment course,the total cost of treatment in the treatment group was the same as that of the control group.During the follow-up period,more half of the patients in the treatment group were cured,and the cure rate（ 52%） was significantly higher than that of the control group（24%）（P〈0.05）;Compareed with control group,the recurrence of curative group（8%） were significantly lower than that of the control group（ 32%）（ P〈0.05）.Conclusion Seretide combined with tiotropium is effective in the treatment of stable COPD,which is worthy to be pervasively applied in clinic.

关 键 词：慢性阻塞性肺疾病 思力华 舒利迭 联合用药 肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]